胰腺癌是全世界公认的高度恶性疾病之一。由于胰腺癌疾病隐匿、病情发展较快，目前尚无明确有效的治疗方案，基于吉西他滨的联合化疗仍是最主要的临床手段。研究发现胰腺癌细胞对吉西他滨有高度化疗耐药性，因此治疗效果并不理想，而且与细胞毒性药物的联用方案对患者有较强的机体损伤。深入研究发现与吉西他滨可联用于治疗胰腺癌，安全合理并能增加吉西他滨治疗效果的增效剂成为领域重点问题。关注不同增效剂与吉西他滨联合应用的作用机制，分析其应用效果，可为吉西他滨促胰腺癌细胞凋亡作用的发挥提供有利影响，有望为胰腺癌患者带来福音。

Pancreatic cancer is recognized as one of the most highly malignant diseases in the world. Because of the stealthiness and rapid progression of pancreatic cancer, there is no effective treatment scheme. Combined chemotherapies based on gemcitabine are primary clinical methods. Researches found that pancreatic cancer cells had highly chemotherapy resistance to gemcitabine, and its effectiveness was far from the expected result. Moreover, the combination with cytotoxic drugs has strong injuries to patients. Therefore, researchers focus on seeking synergists which can be used with gemcitabine to enhance its pharmacological action in the treatment of pancreatic cancer. To study the mechanism of the combination of synergists and gemcitabine may provide it with positive impact on promoting cell apoptosis, which will bring benefit for pancreatic cancer patients.